Posted on by admin

Familial Chylomicronemia Syndrome Market 2032: Epidemiology Insights, Pipeline Updates, Regulatory Milestones by DelveInsight | Arrowhead Pharma, Visirna Therapeutics HK Ltd, Ionis Pharma, Novartis

Familial Chylomicronemia Syndrome Market 2032: Epidemiology Insights, Pipeline Updates, Regulatory Milestones by DelveInsight | Arrowhead Pharma, Visirna Therapeutics HK Ltd, Ionis Pharma, Novartis
The Familial Chylomicronemia Syndrome Market size was valued approximately USD 15 million in 2022 and the report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the 7MM.

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome Market Forecast

 

Some of the key facts of the Familial Chylomicronemia Syndrome Market Report: 

  • The Familial Chylomicronemia Syndrome market size was valued approximately USD 15 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In May 2023, Arrowhead Pharmaceuticals has finished enrolling participants for its Phase III PALISADE trial investigating ARO-APOC3 for treating familial chylomicronemia syndrome (FCS), an extremely rare genetic disorder typically caused by various single-gene mutations. The international AROAPOC3-3001 PALISADE trial will evaluate the effectiveness and safety of the investigational RNAi therapeutic ARO-APOC3 in adult patients with FCS.

  • In the 7MM, there are now 2,989 diagnosed prevalent cases of FCS, with an expected rise to 3,032 cases by 2032. In terms of diagnosed prevalence, the US was followed by Japan

  • Nearly 22.9% of the 7MM’s diagnosed prevalent FCS cases were located in the US in 2021, and by 2032, that percentage is projected to rise even further

  • Németh et al. (2022), who examined the medical data of 1,342,124 patients, calculated that the frequency of FCS in the region of Central Europe was 19.4 per million. It’s possible that the variation in disease prevalence was caused by the study’s use of a population that was treated or examined in a hospital

  • In 2021, the United States had about 1340 prevalent cases, a number anticipated to rise by 2032.

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, and others

  • The Familial Chylomicronemia Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics.

 

Familial Chylomicronemia Syndrome Overview

An extremely rare hereditary condition known as familial chylomicronemia syndrome (FCS) inhibits the body from metabolising dietary fats, or triglycerides, that are eaten. Large structures in the blood known as chylomicrons assist transport these triglycerides to various locations throughout the body where they are required for energy production and fat storing.

 

Get a Free sample for the Familial Chylomicronemia Syndrome Market Report:

https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

 

Familial Chylomicronemia Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Familial Chylomicronemia Syndrome Epidemiology Segmentation:

The Familial Chylomicronemia Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Familial Chylomicronemia Syndrome

  • Prevalent Cases of Familial Chylomicronemia Syndrome by severity

  • Gender-specific Prevalence of Familial Chylomicronemia Syndrome

  • Diagnosed Cases of Episodic and Chronic Familial Chylomicronemia Syndrome

 

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome epidemiology trends @ Familial Chylomicronemia Syndrome Epidemiology Forecast

 

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Familial Chylomicronemia Syndrome Therapies and Key Companies

  • ARO-APOC3: Arrowhead Pharma

  • VSA001 injection: Visirna Therapeutics HK Limited

  • Olezarsen: Ionis Pharmac

  • LCQ908: Novartis

  • AKCEA-ANGPTL3-LRx: Akcea Therapeutics

  • Volanesorsen: Akcea Therapeutics

 

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome market share @ Familial Chylomicronemia Syndrome Treatment Market

 

Scope of the Familial Chylomicronemia Syndrome Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

  • Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, and others

  • Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies

  • Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Familial Chylomicronemia Syndrome Unmet Needs, KOL’s views, Analyst’s views, Familial Chylomicronemia Syndrome Market Access and Reimbursement 

 

To know more about Familial Chylomicronemia Syndrome companies working in the treatment market, visit @ Familial Chylomicronemia Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Familial Chylomicronemia Syndrome Market Report Introduction

2. Executive Summary for Familial Chylomicronemia Syndrome

3. SWOT analysis of Familial Chylomicronemia Syndrome

4. Familial Chylomicronemia Syndrome Patient Share (%) Overview at a Glance

5. Familial Chylomicronemia Syndrome Market Overview at a Glance

6. Familial Chylomicronemia Syndrome Disease Background and Overview

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Chylomicronemia Syndrome 

9. Familial Chylomicronemia Syndrome Current Treatment and Medical Practices

10. Familial Chylomicronemia Syndrome Unmet Needs

11. Familial Chylomicronemia Syndrome Emerging Therapies

12. Familial Chylomicronemia Syndrome Market Outlook

13. Country-Wise Familial Chylomicronemia Syndrome Market Analysis (2019–2032)

14. Familial Chylomicronemia Syndrome Market Access and Reimbursement of Therapies

15. Familial Chylomicronemia Syndrome Market Drivers

16. Familial Chylomicronemia Syndrome Market Barriers

17.  Familial Chylomicronemia Syndrome Appendix

18. Familial Chylomicronemia Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/